Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study

Ravi Retnakaran, Byung Soo Youn, Ying Liu, Anthony J G Hanley, Nam Seok Lee, Ji Woo Park, Eun Sun Song, Vivian Vu, Wi Kim, Rungsunn Tungtrongchitr, Peter J Havel, Michael M. Swarbrick, Collin Shaw, Gary Sweeney

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.

Original languageEnglish (US)
Pages (from-to)885-893
Number of pages9
JournalClinical Endocrinology
Volume69
Issue number6
DOIs
StatePublished - Dec 2008

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study'. Together they form a unique fingerprint.

  • Cite this

    Retnakaran, R., Youn, B. S., Liu, Y., Hanley, A. J. G., Lee, N. S., Park, J. W., Song, E. S., Vu, V., Kim, W., Tungtrongchitr, R., Havel, P. J., Swarbrick, M. M., Shaw, C., & Sweeney, G. (2008). Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study. Clinical Endocrinology, 69(6), 885-893. https://doi.org/10.1111/j.1365-2265.2008.03264.x